DrugPatentWatch Database Preview
Ipsen Inc Company Profile
What is the competitive landscape for IPSEN INC, and when can generic versions of IPSEN INC drugs launch?
IPSEN INC has two approved drugs.
There are twelve US patents protecting IPSEN INC drugs.
There are fifty-five patent family members on IPSEN INC drugs in twenty-three countries and four supplementary protection certificates in four countries.
Drugs and US Patents for Ipsen Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,492,442 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,364,473 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,782,349 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
Ipsen Inc | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 8,992,970 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Ipsen Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 5,681,814 | ➤ Try a Free Trial |
Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 5,824,642 | ➤ Try a Free Trial |
Ipsen Inc | INCRELEX | mecasermin recombinant | INJECTABLE;SUBCUTANEOUS | 021839-001 | Aug 30, 2005 | 6,207,640 | ➤ Try a Free Trial |
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for Ipsen Inc Drugs
Country | Document Number | Estimated Expiration |
---|---|---|
South Korea | 101376895 | ➤ Try a Free Trial |
Poland | 2861210 | ➤ Try a Free Trial |
Mexico | 2014015391 | ➤ Try a Free Trial |
Canada | 2821167 | ➤ Try a Free Trial |
Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Ipsen Inc Drugs
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
0885 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
2017 00030 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
C/GB97/010 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
2017000042 | Germany | ➤ Try a Free Trial | PRODUCT NAME: LRINOTECAN SUCROSOFAT-SALZ, WIE Z.B. LRINOTECAN SUCROSOFAT-SALZ IN EINEM PEGYLIERTEN LIPOSOM WIE BEISPIELWEISE EINEM LIPOSOM, DAS 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLIN, CHOLESTERIN UND N-(OMEGA-METHOXYPOLY(ETHYLENGLYKOL) (MOLEKULARGEWICHT 2000)OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMIN Z.B. IM MOLVERHAELTNIS 3:2:0,015 UMFASST.; REGISTRATION NO/DATE: EU/1/16/1130 20161014 |
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.